Nephros (NEPH) Common Equity (2010 - 2026)

Nephros' Common Equity history runs 17 years deep, the most recent figure standing at $10.7 million for Q1 2026.

• On a quarterly basis, Common Equity rose 15.18% year-over-year to $10.7 million in Q1 2026; TTM through Mar 2026 was $10.7 million, a 15.18% increase from a year earlier, with the FY2025 full-year figure at $10.2 million, up 18.84% from the prior year.
• Common Equity rose to $10.7 million in Q1 2026 per NEPH's latest filing, from $10.2 million in the prior quarter.
• Across five years, Common Equity topped out at $13.4 million in Q1 2022 and bottomed at $7.9 million in Q2 2024.
• The 5-year median for Common Equity is $8.9 million (2023), against an average of $9.5 million.
• Across the five-year window, Common Equity sank 39.79% in 2022 and gained 22.41% in 2025, its largest moves.
• Year by year, Common Equity stood at $8.9 million in 2022, then retreated by 5.89% to $8.4 million in 2023, then gained by 2.72% to $8.6 million in 2024, then advanced by 18.84% to $10.2 million in 2025, then rose by 4.89% to $10.7 million in 2026.
• Per Business Quant, the three latest NEPH Common Equity figures stand at $10.7 million (Q1 2026), $10.2 million (Q4 2025), and $10.0 million (Q3 2025).